Keywords: alpharx, selects, arx82, advanced, preclin, development, canada
AlphaRx selects ARX82 for advanced preclin development
Article | 24 September 2007
Canada's AlphaRx, a specialty pharmaceutical company, says that its ARX828, an orally-administered, potent and selective inhibitor of inducible nitric oxide ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
